MAP2K1 and non-small cell lung carcinoma: Acquired bypass mechanisms of resistance were also detected in six NSCLC patients, including mutations of RET (M918T, n = 1), MET amplification (n = 2), BRAF (V600E, n = 1), MAP2K1/MEK1 (E102_I103del, n = 1) and PI3KCA (H1074R, n = 1) [47].